Small cell lung cancer (SCLC) is one of the most aggressive forms of lung cancer, with a five-year survival rate of only 5%.

Lung cancer patients receiving immunochemotherapy earlier in the day had a 52% lower risk of progression in a new medical ...

Spatial maps of lung precancer and cancer cells at different points in development advance understanding of the earliest stages of lung cancer Findings highlight inflammation as a driver of lung tumor ...

SAVANNAH and ORCHARD Phase II trials show the addition of savolitinib or datopotamab deruxtecan-dlnk to TAGRISSO upon disease progression demonstrates strong clinical activity New study results ...

Ceralasertib in combination with Imfinzi (durvalumab) did not meet the primary endpoint of overall survival (OS) in the phase ...

The Food and Drug Administration (FDA) has granted traditional approval to Imdelltra ® (tarlatamab-dlle) for the treatment of adults with extensive stage small cell lung cancer (ES-SCLC) with disease ...

How Well Does Tagrisso Work for Lung Cancer? The FDA approved Tagrisso based on clinical trials for EGFR-mutated lung cancer in several different scenarios. Tagrisso was studied in people who had lung ...

The third generation EGFR TKI targets EGFR mutant NSCLC, showing improved progression free survival and fewer adverse events ...

Kathy Hochul signed a law Thursday to require insurance companies to cover lung cancer screening, a move supporters say will help catch the disease before it reaches its deadliest stages. Beginning in ...